Benefits of jejunostomy feeding in patients who underwent gastrectomy for cancer treatment

Table 1 Baseline demographic characteristics of the population, cohort N = 172, n (%)

Variables	J + (n = 60)	J - (n = 112)	P value
Age (years, mean ± SD)	69.4 ± 12.6	70.2 ± 11.2	0.65
Male	43 (71.7)	57 (50.9)	0.01a
H. pylori infection	11 (18.3)	13 (11.6)	0.25
Smoking	6 (10.2)	12 (10.8)	1
Medical background	40 (66.7)	77 (69.4)	0.73
Dementia	5 (8.3)	4 (3.6)	0.28
Stroke	6 (10)	7 (6.2)	0.38
AF	7 (11.7)	8 (7.2)	0.4
CAD	4 (6.7)	7 (6.2)	1
Heart failure	6 (10)	5 (4.5)	0.2
LEAD	4 (6.7)	7 (6.2)	1
Diabetes	15 (25)	28 (25)	1
Other cancer	12 (20)	18 (16.1)	0.53
Abdominal surgery	18 (30)	46 (41.1)	0.19
AC/APA	21 (35.6)	26 (23.9)	0.11
Corticoids/IT	1 (1.7)	2 (1.8)	1
WHO score
0	18 (38.3)	37 (38.9)	0.58
1	20 (42.6)	43 (45.3)
2	5 (10.5)	12 (12.6)
3	4 (8.5)	3 (3.2)

^aP < 0.05.

A group with jejunostomy (J + group) and a group without jejunostomy (J - group) were compared. AC: Anticoagulant; AF: Atrial fibrillation; APA: Antiplatelet agent; CAD: Coronary artery disease; H. pylori: Helicobacter pylori; IT: Immunosuppressive therapy; LEAD: Lower-extremity artery disease; WHO: World Health Organization.